Sumary of Top in rheumatology: Sotrovimab for COVID-19, Xeljanz for ankylosing spondylitis:
- Another top story shared study data on tofacitinib (Pfizer) as a treatment for adults with ankylosing spondylitis..
- The FDA’s authorization of sotrovimab to treat mild-to-moderate COVID-19 in patients aged older than 12 years was the top story in rheumatology last week..
- The FDA has issued an emergency use authorization for the monoclonal antibody sotrovimab sotrovimab (VIR-7831, GlaxoSmithKline) to treat mild-to-moderate COVID-19 in patients at risk for progressing to severe disease, according to a press release..
- Erosive hand osteoarthritis tends to target older adults and women with preexisting OA, and is associated with severe articular structural damage and radiographic progression, according to data published in Arthritis &…